Research - Chuo, Tokyo, Japan
CUORiPS Inc. is a start-up company established in March 2017, to develop and commercialize regenerative medicines/cell therapy products for severe heart failure, based on a technology platform using iPS cell-derived cardiomyocytes.Using a state-of-the-art iPS-related technology platform from Osaka University, we aim to treat various types of heart failure, which is the largest cause of death in the U.S. and Europe, and 2nd largest cause of death in Japan
Gmail
WordPress.org
Google Tag Manager
Mobile Friendly
YouTube